

Photobiomodulation therapy for diabetic foot ulcers

Moulinath Banerjee, Vivien Wheatland, Jane Humphreys, Patricia Vice

Article points

1. Photobiomodulation therapy involves the application of low-level polychromatic, coherent light to stimulate wound healing, as demonstrated in cell culture, animal and human studies.
2. The ulcer closure rate observed in this study suggests a positive role for photobiomodulation therapy in the promotion of healing in diabetic foot ulcers.
3. Any measure that aids closure of diabetic foot ulcers is positive, given the association between ulcers, amputation and morbidity.

Key words:

- Diabetic foot ulcer
- Photobiomodulation
- Wound healing

Moulinath Banerjee is Honorary Clinical Research Fellow at Manchester University, Manchester; Vivien Wheatland and Jane Humphreys are Podiatrists, based at the Royal Preston Hospital, Preston; Patricia Vice is a retired Physician.

A number of studies have suggested that low-level polychromatic, coherent light, described in the clinical setting as “photobiomodulation” therapy, may improve wound healing. In this retrospective cohort study, photobiomodulation therapy was applied to a series of diabetic foot ulcers as an adjunct to traditional diabetic foot ulcer care. Photobiomodulation therapy was well tolerated by the participants, and a wound closure rate of 48.2% by study end was observed. These results suggest that photobiomodulation therapy may be a beneficial adjunct to traditional treatments for diabetic foot ulcers.

It has been estimated that an ulcer will develop on the foot or ankle of 15% of people with diabetes during their lifetime (Boulton, 2004). Various adjunctive physical therapeutic modalities, including ultrasound, electrotherapy and electromagnetic therapy, have been proposed for the treatment of lower-limb ulcers in people with diabetes (Cullum et al, 2001).

Photobiomodulation therapy is a technique whereby low-level polychromatic, coherent light is applied to injured dermis in an attempt to improve wound healing. The non-thermal effects of light between 1–10 J/cm² on biological tissues has been shown to be beneficial in cell culture studies (Bronson et al, 2005).

Using National Aeronautics and Space Administration-developed light-emitting diode (LED) technology, Whelan et al (2001) reported in vitro increases in the

growth of mouse fibroblasts, rat osteoblasts, rat skeletal muscle cells and human epithelial cells. Using the same light source, clinical reductions in wound size in rat studies, and reductions in healing time in human volunteers from the US Navy, were also reported (Whelan et al, 2001). However, data on the use of photobiomodulation therapy to treat diabetic foot ulcers are limited. In their review, Forney and Mauro (1999) concluded that further research is required to evaluate the role of lasers and photobiomodulation therapy in diabetic foot ulcer closure.

The retrospective cohort study reported here assessed the efficacy of photobiomodulation using LED (PLED) on the closure of diabetic foot ulcers.

Methods and participants

Twenty people who presented with diabetic foot ulcers between October 2000 and

June 2002 at the Royal Preston Hospital were included in this study. Data were taken from podiatry and general medical records.

Participants were treated according to a standard protocol for diabetic foot ulcer management (Jeffcoate et al, 2004). This included regular sharp debridement of calluses surrounding the ulcer, use of walking or total-contact casts for off-loading and regular moist dressing. In addition to the traditional management protocols, participants received PLED therapy every 1–3 weeks until their ulcer healed, or until the end of the study period was reached (June 2002). Healing was defined as complete epithelialisation without discharge.

Foot care and PLED therapy were delivered by a trained podiatrist under the supervision of the clinic's consultant physician. Ulcer size was taken as the diameter at its widest point. All participants underwent radiological assessment to exclude underlying osteomyelitis. Wagner's scores (Wagner, 1981) were used to grade the severity of ulceration. Cellulitis was defined as an acute spreading infection extending at least 10 mm beyond the wound margin, with or without purulent discharge, and with or without evidence of systemic infection (e.g. fever, leucocytosis). Those diagnosed with cellulitis had wound swabs sent for bacterial culture and sensitivity testing and were treated with broad-spectrum antibiotics until the results of sensitivity testing allowed for narrowing to a more appropriate agent.

PLED therapy was delivered using the THOR-LX photobiomodulation unit

(THOR Photomedicine, Chesham, UK; *Figures 1–2*). This unit incorporates two LED treatment probes: a single-point probe, and a cluster probe. The cluster probe comprised 34×660 nm 10 mW (power density 50 mW/cm^2) and 35×950 nm 15 mW LEDs (power density 75 mW/cm^2), with an average power density for the whole cluster probe of 62.5 mW/cm^2 . The single-point probe comprised 1×660 nm 10 mW LED (power density 50 mW/cm^2) (THOR Photomedicine, 1998).

Treatment time was typically 60 seconds/cm², with the cluster probe delivering 3.75 J/cm^2 to each treatment site, followed by treatment with the single-point probe around the wound margin at 1 cm intervals. The probes were held as close to the wound as possible without touching its surface. Treatment with the appropriate probe continued until all of the wound, and the surrounding intact tissue, had received a complete dose.

Statistics

Data were analysed for computing odds ratio, 2-tailed Student's *t*-test and Chi-squared test for *P*-values and Spearman's Rank correlation test using SPSS software, version 11.5 (SPSS, Chicago, IL, USA). *P*-values <0.05 were considered to be statistically significant.

Results

Participant characteristics

Baseline participant characteristics are summarised in *Table 1*. Ulcers occurred most frequently in men aged 60–70 years (22.0%), and in women aged 80–90 years (15.0%). In

Page points

1. In addition to the traditional management protocols, participants received photobiomodulation therapy every 1–3 weeks until their ulcer healed, or until the end of the study period was reached.
2. Foot care and photobiomodulation therapy were delivered by a trained podiatrist under the supervision of a consultant physician.
3. The probes were held as close to the wound as possible without touching its surface, and treatment with the appropriate probe continued until all of the wound, and the surrounding intact tissue, had received a complete dose.
4. Ulcers occurred most frequently in men aged 60–70 years (22.0%), and in women aged 80–90 years.



Figures 1–2. Use of a photobiomodulation unit in the clinical setting.

Page points

1. Episodes of ulceration were most commonly limited to soft tissue (77.8%), while 22.2% extended to bone.
2. Wound swabs, taken from ulcers positive for cellulitis, revealed pathogenic organisms in 15 (55.6%) ulcers, the most common isolate being *Staphylococcus aureus* (48.3%).
3. Baseline ulcer size was significantly larger, and cellulitis resolution time significantly longer, in those ulcers that failed to heal ($P=0.02$ and $P=0.04$, respectively).
4. Frequency of photobiomodulation therapy varied from once every 1–3 weeks, and there was no significant difference between those that healed and those that failed to heal in relation to the frequency of therapy.

this series, 25.9% of participants had type 1 diabetes, 66.7% had type 2 diabetes and 7.4% had diabetes secondary to chronic pancreatitis.

Of the 20 participants, nine (33.3%) had two ulcers and the rest (66.7%) had solitary ulcers. Analyses were conducted based on episodes of foot ulceration. A participant with more than one foot ulcer was considered “healed” only when all ulcers present during that episode of ulceration had healed. A total of 27 episodes of foot ulceration were treated during the study period.

Mean ulcer size was 15.7 ± 9.8 mm, taken at its widest point. Episodes of ulceration were most commonly limited to soft tissue (Wagner’s score 2; 77.8%), while 22.2% extended to bone (Wagner’s score 3). Ulcers were frequently located on the plantar aspect of the foot (92.6%), with the most common site of ulceration being the first metatarsal head (30.3%). Sixteen (59.3%) episodes of ulceration were painless. Seven (25.9%) episodes of ulceration were neuropathic, three (11.2%) were ischaemic, and 17 (62.9%) were neuro-ischaemic. There was a history of trauma in one (3.7%) episode.

Cellulitis was present in 33.3% of episodes of ulceration and resolved in an average of 1.9 ± 1.6 weeks. Wound swabs taken from ulcers with cellulitis revealed pathogenic microbes in 15 (55.6%) episodes of ulceration, the most common isolate being *Staphylococcus aureus* (48.3%).

Non-healing versus healed ulcers

Participant characteristics associated with those episodes of ulceration that

healed, and those that did not, are summarised in *Table 2*.

Episodes of ulceration that failed to heal occurred in people with type 2 diabetes or diabetes secondary to chronic pancreatitis. Proliferative diabetic retinopathy was more common in those who failed to heal than those who achieved healing (53.9% vs. 14.3%). Ulcers that failed to heal were significantly larger at baseline than ulcers that progressed to healing (mean 19.4 ± 11.5 mm vs. 11.9 ± 5.8 mm; $P=0.02$; $r=0.4$).

Pathogenic microbes were more frequently isolated in ulcers that failed to heal than those that healed (64.3% vs. 46.2%). Cellulitis was more common (50% vs. 23.1%), and took significantly longer to resolve (mean 2.4 ± 1.7 weeks versus 1.3 ± 1.4 weeks; $P=0.04$), in those ulcers that failed to heal.

There was no significant difference between those that healed and those that failed to heal in relation to age, sex, smoking status, ulcer duration, foot deformity, glycaemic control, or number of ulcers. None of the participants underwent lower-limb amputation during the study period.

PLED therapy

Nine (33.3%) episodes of ulceration were treated with sequential 20 Hz and 5 Hz PLED doses, 16 (59.3%) received 20 Hz doses and two (7.4%) received 5 Hz at 660 nm doses. The PLED dose was decided upon by the treating physician, based on the type, location and size of the ulcer in question. One participant found PLED therapy painful and treatment was discontinued.

	Men (n=11)	Women (n=9)	Group (n=20)
Mean age (years)	65.1 ± 13.9	74.5 ± 14.5	68.9 ± 13.3
Mean duration of diabetes (years)	11.0 ± 4.3	21.2 ± 10.3	15.5 ± 9.0
Mean ulcer duration prior to study (weeks)	5.3 ± 4.1	3.8 ± 2.4	4.6 ± 3.4
Smokers (n [%])	4 (36.4)	2 (22.2)	6 (30)
Mean ulcer size (mm)	16.1 ± 10.2	15.3 ± 9.7	15.7 ± 9.8
Mean Wagner’s score	2.3 ± 0.5	2.2 ± 0.4	2.2 ± 0.5
Mean HbA _{1c} at presentation (%)	7.17 ± 1.38	8.37 ± 1.74	7.95 ± 0.50

Frequency of PLED therapy varied from once every 1–3 weeks (mean 1.7 ± 0.9 weeks). There was no significant difference between those that healed and those that failed to heal in relation to the frequency of PLED therapy. The mean number of PLED therapy sessions received by those whose ulcer healed was 9.2 (95% confidence interval [CI] 4.4–14.1), and 25.0 (95% CI 10.8–39.2) in those who failed to heal during the study period. The mean duration of PLED therapy among those who achieved ulcer healing was 23.4 ± 18.9 weeks. Dividing the study group by the mean number of PLED sessions, there was no significant difference between the two groups with respect to age, duration of diabetes, ulcer duration, cellulitis resolution time, ulcer size or Wagner's score.

Discussion

The effect of light on wound healing has been well demonstrated in the literature (Cavanagh et al, 2005; Grey et al, 2006).

Various mechanistic explanations for the effectiveness of phototherapy in improving wound healing, observed both in vivo and in vitro, are detailed in *Table 3*. The benefits of light therapy on wound healing have been demonstrated both in animals (Al Watban and Andres, 2003; 2006; Whelan et al, 2003; Byrnes et al, 2004; Kawalec et al, 2004; Vink et al, 2005; Rabelo et al, 2006) and humans (Schindl et al, 1999; Landau and Schattner, 2001) with diabetes.

In the cohort reported here, the main factors influencing healing were similar to those reported in previous studies investigating PLED therapy, namely peripheral neuropathy, arterial disease, poor vision, foot deformity and previous ulceration (Boyko et al, 1999; Abbott et al, 2002). Baseline ulcer size, described elsewhere as being a risk factor for non-closure (Oyibo et al, 2001; Sheehan et al, 2003; Zimny et al, 2004), was significantly larger in those that failed to heal, compared with those

Page points

1. The benefits of photobiomodulation therapy on wound healing have been demonstrated both in animals and humans with diabetes.
2. In the cohort reported here, the main factors influencing healing were similar to those reported in previous studies investigating photobiomodulation therapy, namely peripheral neuropathy, arterial disease, poor vision, foot deformity and previous ulceration.
3. Ulcer depth has been reported to be a risk factor for ulcer non-closure, but was not found to be significantly different between the healing and non-healing groups in this cohort.

Table 2. Comparison of characteristic associated with those episodes of ulceration that healed, and those that did not, by study end.[†]

	Healed (<i>n</i> =13)	Non-healing (<i>n</i> =14)
Mean age (years)	70.5 ± 14.5	68.0 ± 15.4
Men (<i>n</i> [%])	6 (46.2)	9 (64.3)
Type of diabetes (<i>n</i> [%])		
Type 1	4 (30.8)	0
Type 2	8 (61.5)	12 (92.9)
Secondary	1 (7.7)	1 (7.1)
Mean duration of diabetes (years)	18.2 ± 10.8	13.0 ± 10.6
Smokers (<i>n</i> [%])	6 (46.2)	2 (14.1)
Foot deformity (<i>n</i> [%])	3 (23.1)	5 (35.7)
Previous foot ulceration (<i>n</i> [%])	8 (61.5)	6 (42.9)
Lower-limb arterial insufficiency (<i>n</i> [%])	8 (61.5)	13 (92.9)
Prevalence of peripheral neuropathy (<i>n</i> [%])	12 (92.3)	11 (78.6)
Cellulitis (<i>n</i> [%])	3 (23.1)	7 (50.0)
Mean time to cellulitis resolution (weeks)*	1.3 ± 1.4	2.4 ± 1.7
Ulcer size (mm)*	11.9 ± 5.8	19.4 ± 11.5
Wagner's score		
2: Soft tissue (<i>n</i> [%])	11 (84.6)	10 (71.4)
3: Bone (<i>n</i> [%])	2 (15.4)	4 (28.6)
Microbial growth (<i>n</i> [%])	6 (46.2)	9 (64.3)

[†]Data were calculated using the episodes of ulceration as the denominator.
**P*<0.05, statistically significant.

Page points

1. The closure rates observed, coupled with the fact that none of the participants underwent an amputation, suggest that photobiomodulation therapy improved wound healing in these diabetic foot ulcers.
2. Any measure that aids closure of diabetic foot ulcers is positive, given the well-established association between ulcers, amputation and morbidity.
3. Larger studies investigating the use of photobiomodulation therapy for the treatment of diabetic foot ulcers is required.

that healed ($P=0.02$). The other significant indicator of non-closure was cellulitis, which took significantly longer to resolve in those ulcers that failed to heal ($P=0.04$). Ulcer depth has similarly been reported to be a risk factor for non-closure (Oyibo et al, 2001; Treece et al, 2004), but was not found to be significantly different between the healing and non-healing groups in this cohort.

In a meta-analysis of ten randomised clinical trials of neuropathic ulcers receiving standard treatment, the closure incidence was 24.2% at 12 weeks and 30.9% at 20 weeks (Margolis et al, 1999), and Harrington et al (2000) found the overall incidence of closure for all diabetic foot ulcers to be 31%. In the cohort reported here, with its high overall incidence of lower-limb ischaemia (77.8%), the incidence of closure was 22.2% at 12 weeks, 29.6% at 20 weeks, and 48.1% by study end. These closure incidences, coupled with the fact that none of the participants underwent an amputation, suggest that PLED therapy improved wound healing in these diabetic foot ulcers.

Limitations

The limitations of this study are that it was not a randomised control trial, and that the number of participants was small. Larger studies investigating the use of PLED therapy for the treatment of diabetic foot ulcers are required.

Conclusion

Given the well-established association between ulcers, amputation and morbidity, any measure that aids closure of diabetic foot ulcers is positive.

PLED therapy is a safe, well-tolerated adjunct to standard wound care treatment for diabetic foot ulceration. While the efficacy of low-level phototherapy has yet to be confirmed by large randomised control trials, the results reported here suggest a positive role for PLED therapy in the promotion of healing of diabetic foot ulcers. ■

Acknowledgements

The authors would like to thank James Carroll of THOR Photomedicine for providing detailed technical specifications of the Thor LX photobiomodulation unit

Table 3. Proposed explanations for the efficacy of phototherapy in wound healing.	
1.	Phototherapy increases local blood flow, a response to laser light devoid of any thermal properties (Schindl et al, 1998).
2.	Phototherapy increases local temperature of the irradiated areas (not due to incident heat, but conversion of light energy to heat energy locally), which leads to induction of proteins of the heat shock groups, especially hsp70. These proteins modulate local growth factors (especially b-fibroblast growth factor) secreted from fibroblasts, thereby promoting local wound repair (Capon and Mordon, 2003; Byrnes et al, 2004).
3.	Phototherapy is reported to induce transformation of fibroblasts to myofibroblasts, which may accelerate the wound healing process (Pourreau-Schneider et al, 1990).
4.	Phototherapy has been demonstrated to increase pro-collagen synthesis in in vitro human embryonic fibroblast cultures (Skinner et al, 1996), subsequently increasing the total collagen content and the tensile strength of the resultant scar (Saperia et al, 1986; Lyons et al, 1987; Greene et al, 2000).
5.	Phototherapy stimulates local cell growth, including that of fibroblasts and epithelial cells (Whelan et al, 2001).
6.	Phototherapy enhances collagen (Abergel et al, 1987), integrin, laminin and gap junction protein gene expression (Whelan et al, 2003).

and for supplying photographs of the unit in use. The authors would also like to thank Professor Rayaz Malik of the Manchester Royal Infirmary for his advice on the preparation of this manuscript.

- Abbott CA, Carrington AL, Ashe H et al (2002) The north-west diabetes foot care study: Incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. *Diabet Med* 19: 377–84
- Abergel RP, Lyons RF, Castel JC et al (1987) Biostimulation of wound healing by lasers: Experimental approaches in animal models and in fibroblast cultures. *J Dermatol Surg Oncol* 13: 127–33
- Al Watban FA, Andres BL (2003) Polychromatic LED therapy in burn healing of non-diabetic and diabetic rats. *J Clin Laser Med Surg* 21: 249–58
- Al Watban FA, Andres BL (2006) Polychromatic LED in oval full-thickness wound healing in non-diabetic and diabetic rats. *Photomed Laser Surg* 24: 10–16
- Boulton AJ (2004) The diabetic foot: From art to science. The 18th Camillo Golgi lecture. *Diabetologia* 47: 1343–53
- Boyko EJ, Ahroni JH, Stensel V et al (1999) A prospective study of risk factors for diabetic foot ulcer. The Seattle Diabetic Foot Study. *Diabetes Care* 22: 1036–42
- Brondon P, Stadler I, Lanzafame RJ (2005) A study of the effects of phototherapy dose interval on photobiomodulation of cell cultures. *Lasers Surg Med* 36: 409–13
- Byrnes KR, Barna L, Chenault VM et al (2004) Photobiomodulation improves cutaneous wound healing in an animal model of type 2 diabetes. *Photomed Laser Surg* 22: 281–90
- Capon A, Mordon S (2003) Can thermal lasers promote skin wound healing? *Am J Clin Dermatol* 4: 1–12
- Cavanagh PR, Lipsky BA, Bradbury AW et al (2005) Treatment for diabetic foot ulcers. *Lancet* 12: 1725–35
- Cullum N, Nelson EA, Flemming K et al (2001) Systematic reviews of wound care management: (5) beds; (6) compression; (7) laser therapy, therapeutic ultrasound, electrotherapy and electromagnetic therapy. *Health Technol Assess* (online journal). Available from: <http://tinyurl.com/d8mtmu> (accessed 21.02.09)
- Forney R, Mauro T (1999) Using lasers in diabetic wound healing. *Diabetes Technol Ther* 1: 189–92
- Greene D, Egbert BM, Utley DS et al (2000) In vivo model of histologic changes after treatment with the superpulsed CO₂ laser, erbium: YAG laser, and blended lasers: A 4- to 6-month prospective histologic and clinical study. *Lasers Surg Med* 27: 362–72
- Grey JE, Enoch S, Harding KG (2006) Wound assessment. *BMJ* 4: 285–8
- Harrington C, Zagari MJ, Corea J et al (2000) A cost analysis of diabetic lower-extremity ulcers. *Diabetes Care* 23: 1333–8
- Jeffcoate WJ, Price P, Harding KG (2004) Wound healing and treatments for people with diabetic foot ulcers. *Diabetes Metab Res Rev* 20(Suppl 1): S78–S89
- Kawalec JS, Hetherington VJ, Pfennigwerth TC et al (2004) Effect of a diode laser on wound healing by using diabetic and nondiabetic mice. *J Foot Ankle Surg* 43: 214–20
- Landau Z, Schattner A (2001) Topical hyperbaric oxygen and low energy laser therapy for chronic diabetic foot ulcers resistant to conventional treatment. *Yale J Biol Med* 74: 95–100
- Lyons RF, Abergel RP, White RA (1987) Biostimulation of wound healing in vivo by a helium-neon laser. *Ann Plast Surg* 18: 47–50
- Margolis DJ, Kantor J, Berlin JA (1999) Healing of diabetic neuropathic foot ulcers receiving standard treatment. A meta-analysis. *Diabetes Care* 22: 692–5
- Oyibo SO, Jude EB, Tarawneh I et al (2001) The effects of ulcer size and site, patient's age, sex and type and duration of diabetes on the outcome of diabetic foot ulcers. *Diabet Med* 18: 133–8
- Pourreau-Schneider N, Ahmed A, Soudry M et al (1990) Helium-neon laser treatment transforms fibroblasts into myofibroblasts. *Am J Pathol* 137: 171–8
- Rabelo SB, Villaverde AB, Nicolau R et al (2006) Comparison between wound healing in induced diabetic and nondiabetic rats after low-level laser therapy. *Photomed Laser Surg* 24: 474–9
- Saperia D, Glassberg E, Lyons RF et al (1986) Demonstration of elevated type I and type III procollagen mRNA levels in cutaneous wounds treated with helium-neon laser. Proposed mechanism for enhanced wound healing. *Biochem Biophys Res Commun* 138: 1123–8
- Schindl A, Schindl M, Schon H et al (1998) Low-intensity laser irradiation improves skin circulation in patients with diabetic microangiopathy. *Diabetes Care* 21: 580–4
- Schindl A, Schindl M, Pernerstorfer-Schon H (1999) Diabetic neuropathic foot ulcer: Successful treatment by low-intensity laser therapy. *Dermatology* 198: 314–16
- Sheehan P, Jones P, Caselli A et al (2003) Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. *Diabetes Care* 26: 1879–82
- Skinner SM, Gage JP, Wilce PA et al (1996) A preliminary study of the effects of laser radiation on collagen metabolism in cell culture. *Aust Dent J* 41: 188–92
- THOR Photomedicine (1998) *Thor LX Operating Manual: OM03*. THOR Photomedicine, Chesham
- Treece KA, Macfarlane RM, Pound N et al (2004) Validation of a system of foot ulcer classification in diabetes mellitus. *Diabet Med* 21: 987–91
- Vinck EM, Cagnie BJ, Cornelissen MJ et al (2005) Green light emitting diode irradiation enhances fibroblast growth impaired by high glucose level. *Photomed Laser Surg* 23: 167–71
- Wagner Jr FW (1981) The dysvascular foot: A system for diagnosis and treatment. *Foot Ankle* 2: 64–122
- Whelan HT, Smits Jr RL, Buchman EV et al (2001) Effect of NASA light-emitting diode irradiation on wound healing. *J Clin Laser Med Surg* 19: 305–14
- Whelan HT, Buchmann EV, Dhokalia A et al (2003) Effect of NASA light-emitting diode irradiation on molecular changes for wound healing in diabetic mice. *J Clin Laser Med Surg* 21: 67–74
- Zimny S, Schatz H, Pfohl M (2004) The effects of ulcer size on the wound radius reductions and healing times in neuropathic diabetic foot ulcers. *Exp Clin Endocrinol Diabetes* 112: 191–4

“Given the well-established association between ulcers, amputation and morbidity, any measure that aids closure of diabetic foot ulcers is positive.”